VANTA On Other Exchanges
Symbol
Exchange
Mumbai

vanta bioscience ltd (VANTA) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANTA BIOSCIENCE LTD (VANTA)
\

Related News

No related news articles were found.

vanta bioscience ltd (VANTA) Related Businessweek News

No Related Businessweek News Found

vanta bioscience ltd (VANTA) Details

Vanta Bioscience Limited operates as a preclinical contract research organization in India. It offers preclinical safety assessment services for clients from pharmaceutical, medical device, nutraceutical, feed additive, biotech, agrochemical, cosmetic, and chemical industries. The company also provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients, excipients, extractable, and leachables, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. In addition, it offers services for health based or occupational exposure limits for pharmaceutical manufacturers. Further, the company provides acute, sub-acute toxicology, and in vitro and in vivo genotoxicity testing services, as well as battery of routine pharmacology and clinical chemistry assays in rodent species and rabbits. Additionally, it has an agreement with HongKong Thinkway Trading Limited for providing business consulting and procuring sales services in Greater China, the Asia Pacific, and Latin America regions. The company was incorporated in 2016 and is based in Secunderabad, India.

Founded in 2016

vanta bioscience ltd (VANTA) Top Compensated Officers

CEO & Whole Time Director
Total Annual Compensation: 3.0M
MD & Director
Total Annual Compensation: 2.8M
Whole-Time Director
Total Annual Compensation: 5.9M
Company Secretary & Compliance Officer
Total Annual Compensation: 220.0K
Compensation as of Fiscal Year 2018.
vanta bioscience ltd
Vanta Bioscience Limited Reports Standalone and Consolidated Audited Earnings Results for the Half Year and Full Year Ended March 31, 2019

Vanta Bioscience Limited reported standalone and consolidated audited earnings results for the half year and full year ended March 31, 2019. For the half year, on standalone basis, the company reported revenue from operations of INR 64.026 million against INR 34.925 million a year ago. Total revenue was INR 65.558 million against INR 35.453 million a year ago. Net Profit from ordinary activities after tax was INR 4.008 million against loss of INR 0.236 million a year ago. Earnings per basic and diluted share (before and after extra ordinary items) was INR 0.77 against INR 0.0 a year ago. For the year, on standalone basis, the company reported revenue from operations of INR 124.248 million against INR 29.86 million a year ago. Total revenue was INR 126.536 million against INR 40.388 million a year ago. Net Profit from ordinary activities after tax was INR 6.938 million against INR 0.273 million a year ago. Earnings per basic and diluted share (before and after extra ordinary items) was INR 1.17 against INR 0.05 a year ago. For the half year, on consolidated basis, the company reported revenue from operations of INR 64.606 million. Total revenue was INR 66.1455 million. Net Profit from ordinary activities after tax was INR 4.035 million. Earnings per basic and diluted share (before and after extra ordinary items) was INR 0.78. For the year, on consolidated basis, the company reported revenue from operations of INR 124.828 million against INR 39.860 million a year ago. Total revenue was INR 127.1235 million against INR 40.388 million a year ago. Net Profit from ordinary activities after tax was INR 6.965 million against INR 0.273 million a year ago. Earnings per basic and diluted share (before and after extra ordinary items) was INR 1.19 against INR 0.05 a year ago.

Vanta Bioscience Limited Announces Director Changes

Vanta Bioscience Limited at its board meeting held on May 22, 2019, appointed Dr. Yogeswara Rao Danda as Additional Director (Independent Category), effective May 22, 2019 and took note of resignation of Dr. Iang Bahadur Gupta as Independent Director Dr. Iang Bahadur Gupta has submitted his resignation as Independent Director, effective May 22, 2019 due to his pre-occupation. Dr. D. Yogeswara Rao is currently a visiting professor at University of Hyderabad, Hyderabad for Innovation and entrepreneurship. He is also a consultant to CSIR-IICT. He served as Adviser at the office of Principal scientific Adviser to Government of India, New Delhi before superannuation. The company also reconstituted the audit committee, stakeholder’s relationship committee and nomination & remuneration committee.

Vanta Bioscience Limited to Report Second Half, 2019 Results on May 22, 2019

Vanta Bioscience Limited announced that they will report second half, 2019 results on May 22, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

VANTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VANTA.
View Industry Companies
 

Industry Analysis

VANTA

Industry Average

Valuation VANTA Industry Range
Price/Earnings 100.0x
Price/Sales 7.7x
Price/Book 4.3x
Price/Cash Flow 72.0x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VANTA BIOSCIENCE LTD, please visit www.vantabio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.